BioRa WKN: A3C9XF ISIN: US0906556065 Kürzel: BRTX Forum: Aktien User: DeRitter

As of March 19, 2026, BioRestorative Therapies (NASDAQ: BRTX) announced positive, blinded Phase 2 data for its BRTX-100 stem cell therapy, demonstrating improved pain and function in chronic lumbar disc disease. The findings, based on approximately 45 patients, will be presented at the 2026 Orthopaedic Research Society Annual Meeting. Investing News Network Investing News Network Key Recent Developments: BRTX-100 Phase 2 Data: The company is developing BRTX-100, an autologous (patient-derived) mesenchymal stem cell therapy targeting non-surgical treatment for chronic lumbar disc issues. Data suggests reduced pain and improved mobility in treated patients. Trial Presentation: The findings will be highlighted on March 28, 2026, at the Orthopaedic Research Society Annual Meeting in Charlotte, North Carolina. Corporate Update: BioRestorative continues to develop its ThermoStem® program (targeting obesity/metabolic disorders) and maintains a commercial BioCosmeceutical platform in their cGMP, ISO-7 certified clean room facility. Market Position: The company has reported securing intellectual property for its technology in Japan and has seen significant interest from financial analysts regarding its potential market upside. Stock Titan Stock Titan +3